UY27354A1 - Proceso para la purificación de proteínas farmacologicamente activas a traves de cromatografía de intercambio catiónico - Google Patents

Proceso para la purificación de proteínas farmacologicamente activas a traves de cromatografía de intercambio catiónico

Info

Publication number
UY27354A1
UY27354A1 UY27354A UY27354A UY27354A1 UY 27354 A1 UY27354 A1 UY 27354A1 UY 27354 A UY27354 A UY 27354A UY 27354 A UY27354 A UY 27354A UY 27354 A1 UY27354 A1 UY 27354A1
Authority
UY
Uruguay
Prior art keywords
purification
exchange chromatography
pharmacologically active
proteins
cationic exchange
Prior art date
Application number
UY27354A
Other languages
English (en)
Inventor
Lucia Scapol
Giuseppe Visconi
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Publication of UY27354A1 publication Critical patent/UY27354A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • C07K14/765Serum albumin, e.g. HSA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/18Ion-exchange chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/56IFN-alpha
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/811Interferon

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se basa en la utilización de cromatografía de intercambio catiónico sobre una matriz sólida, llevado a cabo a un nivel de pH, más alto con respecto al pH correspondiente al punto isoeléctrico, pl, de las proteínas a ser purificadas, siendo que a este nivel de pH, sin embargo, dichas proteínas aún permanecen absorbidas. Utilizan soluciones buffer con valores de pH de intensidad iónica que se ajustan cada tanto al tipo de proteína farmacológicamente activa a ser purificada a modo de obtener dicho resultado. El proceso se encuentra dirigido principalmente a la purificación de las proteínas interferona y albúmina.
UY27354A 2001-07-06 2002-06-24 Proceso para la purificación de proteínas farmacologicamente activas a traves de cromatografía de intercambio catiónico UY27354A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001BO000426A ITBO20010426A1 (it) 2001-07-06 2001-07-06 Processo per la purificazione di proteine farmacologicamente attive mediante cromatografia in scambio cationico

Publications (1)

Publication Number Publication Date
UY27354A1 true UY27354A1 (es) 2003-04-30

Family

ID=11439471

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27354A UY27354A1 (es) 2001-07-06 2002-06-24 Proceso para la purificación de proteínas farmacologicamente activas a traves de cromatografía de intercambio catiónico

Country Status (27)

Country Link
US (1) US6866782B2 (es)
EP (1) EP1273592B1 (es)
JP (1) JP3940037B2 (es)
KR (1) KR100771252B1 (es)
CN (1) CN100484954C (es)
AR (1) AR034663A1 (es)
AT (1) ATE307824T1 (es)
BG (1) BG65748B1 (es)
BR (1) BR0202431A (es)
CA (1) CA2388716C (es)
CU (1) CU23149A3 (es)
DE (1) DE60206847T2 (es)
DK (1) DK1273592T3 (es)
DZ (1) DZ3236A1 (es)
EG (1) EG23150A (es)
ES (1) ES2250544T3 (es)
HR (1) HRP20020480B1 (es)
HU (1) HUP0202124A2 (es)
IT (1) ITBO20010426A1 (es)
ME (1) MEP3408A (es)
MX (1) MXPA02006303A (es)
PL (1) PL209954B1 (es)
RS (1) RS51512B (es)
RU (1) RU2274471C2 (es)
SI (1) SI1273592T1 (es)
SK (1) SK287827B6 (es)
UY (1) UY27354A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1628729A2 (en) 2003-05-16 2006-03-01 Cryobiophysica, Inc. External gradient chromatofocusing
WO2005100379A1 (ja) * 2004-03-30 2005-10-27 Hiroshi Yanagisawa タンパク質の分離方法
US7943046B2 (en) * 2004-10-01 2011-05-17 Agilent Technologies, Inc Methods and systems for on-column protein delipidation
US7449116B2 (en) * 2004-10-01 2008-11-11 Agilent Technologies, Inc. Methods and systems for protein separation
HU230758B1 (hu) * 2006-04-12 2018-03-28 Crealta Pharmaceuticals LLC 100% Fehérjék tisztítása kationos felületaktív anyaggal
US20100261275A1 (en) * 2007-12-10 2010-10-14 Yves Durocher Production of Recombinant Interferon Proteins
DE102009032179A1 (de) 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
CN101768601B (zh) * 2010-02-01 2013-08-07 山东泉港药业有限公司 一种重组人血白蛋白—干扰素α2b的生产方法
SG10201605397PA (en) * 2011-07-01 2016-08-30 Hoffmann La Roche Method For Separation Of Monomeric Polypeptides From Aggregated Polypeptides
US8921113B2 (en) 2012-12-21 2014-12-30 Dionex Corporation Buffer kit and method of generating a linear pH gradient
WO2014137903A2 (en) 2013-03-08 2014-09-12 Genzyme Corporation Integrated continuous manufacturing of therapeutic protein drug substances
CN104236983A (zh) * 2013-06-14 2014-12-24 中国科学院大连化学物理研究所 溶液样品中含长烷基链的离子液体的去除方法
TWI671312B (zh) 2014-01-17 2019-09-11 美商健臻公司 無菌層析法及製法
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
WO2016079598A1 (en) * 2014-11-18 2016-05-26 Unichem Laboratories Limited An improved process for the preparation of pharmacopoeial grade interferon alpha 2b
CN106496302B (zh) * 2015-09-08 2021-12-10 三生国健药业(上海)股份有限公司 一种用离子交换层析纯化蛋白质的方法
GB201517450D0 (en) * 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
CN108367245A (zh) * 2015-12-09 2018-08-03 巴斯夫欧洲公司 在解吸条件下从发酵固体纯化蛋白质的方法
GB2568936B (en) 2017-12-01 2019-12-25 Ford Global Tech Llc Liquid cooled injector
US11369703B2 (en) 2018-08-31 2022-06-28 Genzyme Corporation Sterile chromatography resin and use thereof in manufacturing processes
US11022585B2 (en) * 2019-06-09 2021-06-01 Dionex Corporation Methods and systems for optimizing buffer conditions with liquid chromatography
CN111138523A (zh) * 2019-12-10 2020-05-12 天津生机集团股份有限公司 一种从重组鸡干扰素α复性液中纯化制备重组鸡干扰素α的方法
CN113968900B (zh) * 2020-07-23 2023-07-25 中元汇吉生物技术股份有限公司 一种纯化C1q蛋白的方法
CN115918902A (zh) * 2022-12-19 2023-04-07 新疆农业科学院农业质量标准与检测技术研究所 一种通过微水波扩散重力法预处理葡萄脱水并获取高酚葡萄提取物的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228154A (en) * 1979-02-26 1980-10-14 Armour Pharmaceutical Company Purification of plasma albumin by ion exchange chromatography
US4534906A (en) * 1982-11-01 1985-08-13 Genentech, Inc. Removal of impurities from human leukocyte interferon preparations
DE3515336C2 (de) * 1985-04-27 1994-01-20 Boehringer Ingelheim Int Verfahren zur Herstellung und Reinigung von â-Interferon
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
US4732683A (en) * 1986-12-02 1988-03-22 Biospectrum, Inc. Purification method for alpha interferon
US4765903A (en) * 1987-10-06 1988-08-23 Interferon Sciences, Inc. Purification of monomeric interferon
US5250662A (en) * 1989-10-05 1993-10-05 Alpha Therapeutic Corporation Albumin purification
US5849874A (en) * 1991-07-12 1998-12-15 Gist-Brocades, N.V. Process for the purification of serum albumin
IT1262899B (it) * 1992-03-27 1996-07-22 Sclavo Spa Processo per l'isolamento di fattore ix, fattore x e fattore ii altamente purificati dal complesso protrombinico o dal plasma umano
US5440018A (en) * 1992-05-20 1995-08-08 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same
US5521287A (en) * 1992-05-20 1996-05-28 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same
US5728553A (en) * 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5367054A (en) * 1993-04-12 1994-11-22 Stolle Research & Development Corp. Large-scale purification of egg immunoglobulin
DK0679718T3 (da) * 1994-04-09 2001-10-22 Hoffmann La Roche Fremgangsmåde til fremstilling af alfa-interferon
JP3702474B2 (ja) * 1994-06-01 2005-10-05 三菱ウェルファーマ株式会社 血清アルブミン製剤の製造方法
US5486470A (en) * 1994-07-21 1996-01-23 Merck & Co., Inc. Purified herpes simplex virus protease and methods of purification
DE69532492T2 (de) 1994-08-31 2004-12-02 Mitsubishi Pharma Corp. Verfahren zur Reinigung von rekombinantem menschlichem Serumalbumin
EP0871671A1 (en) * 1995-09-07 1998-10-21 PPL Therapeutics (Scotland) Limited Purification of alpha-1 proteinase inhibitor
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process

Also Published As

Publication number Publication date
KR100771252B1 (ko) 2007-10-30
ATE307824T1 (de) 2005-11-15
CA2388716C (en) 2008-01-08
JP2003096092A (ja) 2003-04-03
ES2250544T3 (es) 2006-04-16
RU2274471C2 (ru) 2006-04-20
EP1273592A3 (en) 2003-03-19
HRP20020480B1 (en) 2006-11-30
KR20030005005A (ko) 2003-01-15
HRP20020480A2 (en) 2003-02-28
YU50502A (sh) 2005-09-19
RU2002117383A (ru) 2004-01-27
CN1396176A (zh) 2003-02-12
SI1273592T1 (sl) 2006-02-28
CN100484954C (zh) 2009-05-06
EG23150A (en) 2004-05-31
PL209954B1 (pl) 2011-11-30
CU23149A3 (es) 2006-06-29
ITBO20010426A1 (it) 2003-01-06
ITBO20010426A0 (it) 2001-07-06
BR0202431A (pt) 2003-09-09
CA2388716A1 (en) 2003-01-06
AR034663A1 (es) 2004-03-03
US6866782B2 (en) 2005-03-15
JP3940037B2 (ja) 2007-07-04
SK8592002A3 (en) 2003-01-09
BG106768A (en) 2003-05-30
RS51512B (sr) 2011-06-30
EP1273592B1 (en) 2005-10-26
EP1273592A2 (en) 2003-01-08
HU0202124D0 (es) 2002-09-28
MEP3408A (en) 2010-10-10
SK287827B6 (sk) 2011-11-04
MXPA02006303A (es) 2003-02-10
HUP0202124A2 (hu) 2003-10-28
DE60206847D1 (de) 2005-12-01
DE60206847T2 (de) 2006-07-06
DK1273592T3 (da) 2006-01-02
DZ3236A1 (fr) 2005-04-20
US20030010715A1 (en) 2003-01-16
BG65748B1 (bg) 2009-09-30
PL354769A1 (en) 2003-01-13

Similar Documents

Publication Publication Date Title
UY27354A1 (es) Proceso para la purificación de proteínas farmacologicamente activas a traves de cromatografía de intercambio catiónico
MEP3708A (en) Pharmaceutical compositions from beard lichen (usnea barbata) and st. john's wort (hypericum perforatum) and their use
AR012010A1 (es) Metodo para el procesamiento de una solucion acuosa de proteina c activada
ATE375272T1 (de) Fahrzeugscheinwerfer
DE60040012D1 (de) Rekombinantes gelatin in impstoffen
EA200500019A1 (ru) Ксиланазы, кодирующие их нуклеиновые кислоты и способы их получения и применения
BR0212256A (pt) Proteìnas de fusão de transferrina modificadas
EA200100749A1 (ru) Синтетические пептиды, обладающие поверхностной активностью, и их применение для приготовления синтетического сурфактанта
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
ATE342359T1 (de) Design von beta-faltblatt-proteinen mit spezifischen bindungseigenschaften
TR200100056T2 (tr) Nörotrofik faktörler
DE59903410D1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
DE60204225D1 (de) Verwendung von biologisch aktivem glas zum schneiden von biologisch aktivem glas
EA200000911A1 (ru) Новые кристаллические формы антивирусного соединения бензимидазола
CY1107514T1 (el) Μια μεθοδος για την εκχυλιση, καθαρισμο και ενζυματικη τροποποιηση της α’ υπομοναδας σογια 7s σφαιρινης για να χρησιμοποιηθει ως παραγων που προκαλει υποχολεστepολαιμια
BR0312521A (pt) Métodos para a separação e a purificação de fibrinogênio e de pelo menos uma outra proteìna e para a co-purificação de fibrinogênio e de fator xiii, uso de cromatografia de afinidade com ìon de metal imobilizado, fibrinogênio, kit farmacêutico, e, formulações farmacêutica e de fibrinogênio liofilizado
BRPI0407533A (pt) proteìnas de fusão e muteìnas do interferon alfa com propriedades melhoradas
BR0014758A (pt) Sistemas e métodos para expressão de proteìna com alto rendimento
PT1062244E (pt) Metodos melhorados para produzir proteinas do factor viii
ES2098379T3 (es) Procedimiento para la reactivacion de una proteina desnaturalizada.
BR0214867A (pt) Métodos para a configuração de lentes de contato
PE20060296A1 (es) Composicion farmaceutica que contiene interferon muteina
BR9004693A (pt) Solucao aquosa,processo para aumentar a concentracao de proteina de uma proteina em uma solucao aquosa,e composicao farmaceutica
DE59813886D1 (de) Signalleuchte
FR2883215B1 (fr) Procede d'usinage d'une face de lentille optalmique prismee au centre

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20141217